SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-003346
Filing Date
2024-01-23
Accepted
2024-01-22 21:17:49
Documents
17
Period of Report
2024-01-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43454
2 ex10-1.htm EX-10.1 48211
3 ex10-2.htm EX-10.2 65720
4 ex10-3.htm EX-10.3 28897
5 ex99-1.htm EX-99.1 12706
6 ex10-3_001.jpg GRAPHIC 4370
  Complete submission text file 0001493152-24-003346.txt   407403

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE vtro-20240118.xsd EX-101.SCH 3033
8 XBRL LABEL FILE vtro-20240118_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE vtro-20240118_pre.xml EX-101.PRE 22371
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3082
Mailing Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209
Business Address 3200 CHERRY CREEK DRIVE SOUTH SUITE 410 DENVER CO 80209 8558487627
Vitro Biopharma, Inc. (Filer) CIK: 0000793171 (see all company filings)

IRS No.: 841012042 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-41766 | Film No.: 24550329
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)